In conclusion, we have demonstrated that 1) FFPE biopsy samples of HCC can be used for targeted DNA and RNA sequencing, 2) the tumor mutational burden is a candidate predictor of sorafenib effectiveness, and 3) the tumor gene expressions of NRG1, TGFa, and PECAM1 are candidate markers for the prediction of sorafenib effectiveness. This evidence concerns the gene PECAM1 and hepatocellular carcinoma.